Main Article Content


COVID-19 outbreak is currently being concerned for managing patients with
immunological disorders nowadays, including SLE. Lupus is a complex
autoimmune disease characterized by the presence of autoantibodies that against
cell nucleus involved many organs in the body. Patients with SLE will increase
risk of severe infection because the intrinsic respond attack with their immune
respond though immunosuppressive drugs consumption, and will potentially
damage some organs target associated with their disease. Lupus have multiple
clinical manifestations with a fluctuating symptom. Patient who come with the
symptom ofbreathlessness will getworse day by day. The symptom could be felt in
the same time as fatigue, joint pain, hair loss, malar rash, oral ulcer, pleural
effusion and swollen feet. There's a patient with antinuclear antibody positive for
anti-smith and anti-Ro/SS-A. She was diagnosed with COVID-19, SLE with
nephritis, haemolytic anemia, vasculitis and pleural effusions. The clinical
manifestations of this patient indicate a COVID-19 with lupus nephritis that has
severe disease. She was being treated with methylprednisolone and
hydroxychloroquine for SLE and azithromycin plus oseltamivir as a therapy for
COVID-19. The effect of hydroxychloroquine on SARS-CoV-2 was better seen in
patients with SLE who gotthe medication regularly. Patients went home after 24
days of hospitalization after negative RT-PCR results and clinical improvement of


COVID-19 Hydroxychloroquine Lupus nephritis SLE

Article Details

How to Cite
Putra, R. A., Raveinal, Fauzar, & Deka Viotra. (2021). Covid-19 in Lupus Nephritis. Bioscientia Medicina : Journal of Biomedicine and Translational Research, 5(7), 670-675.